[1]McMillan HJ, Gregas M, Darras BT, Kang PB. Serum transaminase levels in boys with duchenne and becker muscular dystrophy. Pediatrics 2011 ; 127 (1) : e132-6.
[2]Wroblewski F. The clinical significance of transaminase activities of serum. Am J Med. 1959;27:911-923.
[3]Etienne E, Hanser A-M, Woehl-Kremer B, Mohseni-Zadeh M, Blaison G, Martinot M. Macroenzymes: macro-ASAT et macro-CPK. Deux observations et revue de la littérature. /data/revues/02488663/v30i11/S0248866309006596/[Internet]. 2009 Nov 2 [cited 2018 Jul 12] ; Available from : http://www.em-consulte.com/en/article/230527.
[4]Tsung S.H. Creatine kinase isoenzyme patterns in human tissue obtained at surgery. Clin Chem. 1976;22:173-175. 2
[5]Wu H.-J., Chen K.-T., Shee B.-W., Chang H.-C., Huang Y.-J., Yang R.-S. Effects of 24 h ultra-marathon on biochemical and hematological parameters. World J Gastroenterol WJG. 2004;10:2711-2714. 18
[6]Cervellin G, Comelli I, Benatti M, Sanchis-Gomar F, Bassi A, Lippi G. Non-traumatic rhabdomyolysis : Background, laboratory features, and acute clinical management. Clin Biochem 2017 ; 50 (12) : 656-62.
[7]Hoffman EP, Brown RH, Kunkel LM. Dystrophin: The protein product of the duchenne muscular dystrophy locus. Cell 1987 ; 51 (6) : 919-28.
[8]Ryder S, Leadley RM, Armstrong N, et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review. OrphanetJ Rare Dis 2017 ; 12 : 79.
[9]Turner C, Hilton-Jones D. Myotonic dystrophy: Diagnosis, management and new therapies. Curr Opin Neurol 2014 ; 27 (5) : 599-606.
[10]Klein A.F., Gasnier E., Furling D. Gain of RNA function in pathological cases: Focus on myotonic dystrophy. Biochimie. 2011;93:2006-2012. 11
[11]Poynard T., Bedossa P., Naveau S., Lemaigre G., Martin E.D., Chaput J.-C. Perisinusoidal cells (Ito-cells) enlargement in a family with myotonic dystrophy. Liver. 1989;9:276-278. 5
[12]Heatwole C.R., Miller J., Martens B., Moxley R.T. Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1. Arch Neurol. 2006;63:1149-1153. 8
[13]Shieh K, Gilchrist JM, Promrat K. Frequency and predictors of nonalcoholic fatty liver disease in myotonic dystrophy. Muscle Nerve 2010 ; 41 (2) : 197-201.
[14]Clark J.M., Brancati F.L., Diehl A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967. 5
[15]Moxley RT, Kingston WJ, Griggs RC, Livingston JN. Lack of rapid enhancement of insulin action after oral glucose challenge in myotonic dystrophy. Diabetes 1987 ; 36 (6) : 693-701.
[17]Cloots K, Verbeek J, Orlent H, Meersseman W, Cassiman D. Mitochondrial hepatopathy in adults: a case series and review of the literature. Eur J Gastroenterol Hepatol 2013 ; 25 (8) : 892-8.
[20]Milone M., Wong L.-J. Diagnosis of mitochondrial myopathies. Mol Genet Metab. 2013;110:35-41. 1
[21]Spiekerkoetter U. Mitochondrial fatty acid oxidation disorders: Clinical presentation of long-chain fatty acid oxidation defects before and after newborn screening. J Inherit Metab Dis 2010 ; 33 (5) : 527-32.
[22]De Biase I., Viau K.S., Liu A. Diagnosis, treatment, and clinical outcome of patients with mitochondrial trifunctional protein/long-chain 3-hydroxy acyl-coa dehydrogenase deficiency. JIMD Rep. 2016;28:63-71. 31
[23]Tarnopolsky M, Katzberg H, Petrof BJ, et al. Pompe disease: Diagnosis and management. Evidence-based guidelines from a canadian expert panel. Can J Neurol Sci 2016 ; 43 (4) : 472-85.
[24]Konikoff F., Theodor E. Painful muscle cramps. A symptom of liver cirrhosis? J Clin Gastroenterol. 1986;8:669-672. 6
[25]Vidot H., Carey S., Allman-Farinelli M., Shackel N. Systematic review: the treatment of muscle cramps in patients with cirrhosis. Aliment Pharmacol Ther. 2014;40:221-232. 3